Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The collaboration strengthens Bayer’s early pipeline in precision oncology by gaining rights to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : RA Capital Management
Deal Size : $82.6 million
Deal Type : Series B Financing
Cedilla Therapeutics Completes $82.6M Series B Financing
Details : Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumors...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 25, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : RA Capital Management
Deal Size : $82.6 million
Deal Type : Series B Financing
Cedilla Therapeutics Announces $57.6 Million Series B Financing
Details : Proceeds from this financing will support ongoing efforts to build a broad portfolio of small molecule medicines, including the identification and preclinical development of Cedilla’s first two product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 13, 2020
Reset All
